Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05253131 · ClinicalTrials.gov registry record · Phase 2
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT05253131 is a Phase 2 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 41 participants.
The verdict
NCT05253131, a Phase 2 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.
Interventions
- COMBINATION_PRODUCT Selumetinib + ZEN-3694 ± Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2032-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05253131
The ClinicalTrials.gov registry entry for NCT05253131 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selumetinib + ZEN-3694 ± Durvalumab is the first listed.
NCT05253131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05253131 about?
NCT05253131 is a clinical study titled "Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas". A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion ...
What is the current status of trial NCT05253131?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2026-05-15. Estimated completion is 2032-05-15.
What interventions are being tested in trial NCT05253131?
The interventions under investigation include: Selumetinib + ZEN-3694 ± Durvalumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05253131?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.